Carbonic anhydrase inhibitors

Last updated: November 01, 2022

Carbonic anhydrase inhibitors

MEDICINA INTERNA

MEDICINA INTERNA

Immunodeficiencies: Clinical
Antihistamines for allergies
Glucocorticoids
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Infective endocarditis: Clinical
Valvular heart disease: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Sympathomimetics: Direct agonists
Muscarinic antagonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Loop diuretics
Antiplatelet medications
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Thyroid nodules and thyroid cancer: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Clinical
MEN syndromes: Clinical
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Peptic ulcers and stomach cancer: Clinical
Gastroparesis: Clinical
Diarrhea: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Colorectal cancer: Clinical
Diverticular disease: Clinical
Anal conditions: Clinical
Gastrointestinal bleeding: Clinical
Gallbladder disorders: Clinical
Pancreatitis: Clinical
Jaundice: Clinical
Viral hepatitis: Clinical
Cirrhosis: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Zinc deficiency and protein-energy malnutrition: Pathology review
Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Pneumonia: Clinical
Tuberculosis: Pathology review
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
Skin and soft tissue infections: Clinical
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Potassium sparing diuretics
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Cystic fibrosis: Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications

Transcript

Watch video only

Diuretics are medications that act on the kidneys to increase production of urine, and to eliminate water, certain metabolic wastes, and electrolytes from the body.

There are 5 main types of diuretics; carbonic anhydrase inhibitors, osmotic diuretics, thiazide and thiazide-like diuretics, loop diuretics, and last but not least, potassium sparing diuretics - which is the only class of diuretic that retains potassium, rather than wastes it.

Now, the basic unit of the kidney is called a nephron, and each nephron is made up of a glomerulus, which filters the blood. The filtered content goes through the renal tubule, where excess waste, and molecules such as ions and water, are removed or filtered through an exchange between the tubule and the peritubular capillaries. So the renal tubule plays a huge role in secretion and reabsorption of fluid and ions - such as sodium, potassium, and chloride - in order to maintain homeostasis - or the balance of fluid and ions in our body.

The renal tubule has a few segments of its own: the proximal convoluted tubule, the U- shaped loop of Henle, with a thin descending, a thin ascending limb, and a thick ascending limb, and finally, the distal convoluted tubule, which empties into the collecting duct, which collects the urine.

The luminal side of the proximal convoluted tubule is lined by tubule cells, which are also known as brush border cells. The apical surface of these cells, which faces the tubular lumen, is lined with microvilli. Microvilli are tiny projections that increase the cell’s surface area to help it reabsorb more solutes or water.

On the other side is the basolateral surface, which faces the interstitium, or the space between the tubule and the peritubular capillaries. When a molecule of bicarbonate approaches the apical surface of the brush border cell it binds to hydrogen to form carbonic acid. At that point, an enzyme called carbonic anhydrase type 4, which lurks in the tubule among the microvilli like a shark, swims along and splits the carbonic acid into water and carbon dioxide. The overall equation looks like this:

H+ + HCO3- <-> H2CO3 <-> H2O + CO2

The water and carbon dioxide happily diffuse across the membrane into the cells where carbonic anhydrase type 2 facilitates the reverse reaction - combining them to form carbonic acid, which dissolves into bicarbonate and hydrogen.

A sodium bicarbonate cotransporter on the basolateral surface snatches up the bicarbonate and a nearby sodium, and shuttles both into the blood. Meanwhile, that sodium-hydrogen exchanger on the apical surface, pulls sodium into the cell, while pushing hydrogen back into the tubule. So at the end of the day, there’s a movement of bicarbonate and sodium from the tubule to the blood.

Switching gears just a little bit, carbonic anhydrase can also be found in the eyes - specifically, in the middle, vascular tunic of the eye.

Here’s where we can find the ciliary body, which is also lined by epithelial cells that secrete aqueous humor into the posterior chamber of the eye, and carbonic anhydrase helps move bicarbonate from the blood and into that aqueous humor.

Finally, carbonic anhydrase is found in the ventricles of the brain. Here, we can find it in the choroid plexus, which produces cerebrospinal fluid, or CSF for short. The choroid plexus is also lined with epithelial cells, which have carbonic anhydrase that helps bicarbonate move from the blood into the cerebrospinal fluid.

Ok, so carbonic anhydrase inhibitors bind to the carbonic anhydrase enzymes and inhibit them. These medications usually end in -zolamide, and some can be administered by mouth, such as acetazolamide, while others, such as brinzolamide and dorzolamide, can be administered as eye drops for the treatment of glaucoma. But let’s focus on the kidney-related uses first.

Administering acetazolamide leads to a decreased bicarbonate reabsorption in the proximal tubules, so more bicarbonate and sodium get excreted in the urine. So since water flows where the sodium goes, this leads to a mild increase in urine output. This is useful for treating edematous states like pulmonary edema or ascites where fluid builds up in the extracellular space.

As a diuretic, acetazolamide is much weaker than other classes of diuretics like loops and thiazides. So it’s only used to treat edematous states when there’s also alkalosis, or a high blood pH. It also causes urine alkalinization, or an increase in urine pH. If urine pH is too low, some compounds like cystine, or uric acid in the urine can precipitate and form kidney stones. So to prevent kidney stone formation, acetazolamide is given to patients who suffer from cystinuria, which is when there’s too much cystine in the urine, or gout where there’s too much uric acid in the blood, and consequently, the urine.

Now, where carbonic anhydrase inhibitors really come in handy is in the treatment of glaucoma - which is when there’s a high pressure inside the eye, typically because of too much aqueous humor being produced. Although the mechanism isn’t well understood, the secretion of aqueous humor is dependent on bicarbonate production.

So, by inhibiting carbonic anhydrase in the epithelial cells of the ciliary body, there’s decrease aqueous humor production, therefore lowering intraocular pressure. Usually, topical carbonic anhydrase inhibitors like brinzolamide and dorzolamide are used to get the benefits locally, with none of the systemic side effects.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Hypertension" Nature Reviews Disease Primers (2018)
  5. "Hypertension" Nature Reviews Disease Primers (2018)
  6. "Non-Classical Inhibition of Carbonic Anhydrase" International Journal of Molecular Sciences (2016)
  7. "Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis: a systematic review and meta-analysis of randomized controlled trials" Critical Care (2018)